| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study |
| Creator | Alouani et al. |
| Author | E. Alouani |
| Author | M. Mercier |
| Author | C. Flecchia |
| Author | E. Auclin |
| Author | A. Hollebecque |
| Author | T. Mazard |
| Author | A. Turpin |
| Author | S. Pernot |
| Author | R. Cohen |
| Author | M. Dutherage |
| Author | S. Kim |
| Author | F. Sclafani |
| Author | M. Ben-Abdelghani |
| Author | C. Herve |
| Author | T. Aparicio |
| Author | C. De La Fouchardière |
| Author | G. Perkins |
| Author | V. Hautefeuille |
| Author | M. Jaffrelot |
| Author | C. Gallois |
| Author | V. Bongard |
| Author | D. Tougeron |
| Author | R. Guimbaud |
| Abstract | BACKGROUND: Immunotherapy demonstrated remarkable efficacy in metastatic colorectal cancers (mCRCs) with mismatch repair deficiency (MMRd)/microsatellite instability (MSI). However, data regarding efficacy and safety of immunotherapy in the routine clinical practice are scarce. PATIENTS AND METHODS: This is a retrospective, multicenter study aiming to evaluate efficacy and safety of immunotherapy in routine clinical practice and to identify predictive markers for long-term benefit. Long-term benefit was defined as progression-free survival (PFS) exceeding 24 months. All patients who received immunotherapy for an MMRd/MSI mCRC were included. Patients who received immunotherapy in combination with another known effective therapeutic class agent (chemotherapy or tailored therapy) were excluded. RESULTS: Overall, 284 patients across 19 tertiary cancer centers were included. After a median follow-up of 26.8 months, the median overall survival (mOS) was 65.4 months [95% confidence interval (CI) 53.8 months-not reached (NR)] and the median PFS (mPFS) was 37.9 months (95% CI 30.9 months-NR). There was no difference in terms of efficacy or toxicity between patients treated in the real-world or as part of a clinical trial. Overall, 46.6% of patients had long-term benefit. Independent markers associated with long-term benefit were Eastern Cooperative Oncology Group-performance status (ECOG-PS) 0 (P = 0.025) and absence of peritoneal metastases (P = 0.009). CONCLUSIONS: Our study confirms the efficacy and safety of immunotherapy in patients with advanced MMRd/MSI CRC in the routine clinical practice. ECOG-PS score and absence of peritoneal metastases provide simple markers that could help identify patients who benefit the most from this treatment. |
| Publication | ESMO open |
| Volume | 8 |
| Issue | 3 |
| Pages | 101574 |
| Date | 2023-05-25 |
| Journal Abbr | ESMO Open |
| Language | eng |
| DOI | 10.1016/j.esmoop.2023.101574 |
| ISSN | 2059-7029 |
| Library Catalog | PubMed |
| Extra | PMID: 37244250 |
| Tags | immune checkpoint inhibitors (ICI), metastatic colorectal cancer (mCRC), microsatellite instability (MSI), mismatch repair deficient (MMRd) |
| Date Added | 2023/06/08 - 14:47:38 |
| Date Modified | 2024/10/10 - 16:31:28 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
